Urinary tract infections (UTIs) are a persistent global health challenge. Dr. Florian Wagenlehner, Director of Urology at Justus Liebig University, highlights evolving approaches to classifying UTIs, moving beyond simple 'uncomplicated' and 'complicated' to 'localised' or 'systemic' with or without risk factors. This new framework allows for more comparable study cohorts and better understanding of trends, particularly as the global population ages, leading to increased UTI prevalence and severe infections like urosepsis in individuals over 65.
While pathogen profiles remain largely consistent, with Escherichia coli dominating uncomplicated cases and other Enterobacteria and Enterococcus appearing in patients with risk factors, the most significant concern is the rise in antibiotic resistance. This trend, particularly in complicated UTIs, has seen resistance to fluoroquinolones and cephalosporins become endemic, with even low levels of carbapenem-resistant bacteria emerging in regions like Central Europe.
Dr. Wagenlehner identifies resistance to key antibiotics, including fluoroquinolones, third-generation cephalosporins, and emerging carbapenem resistance, as the most concerning patterns. He stresses the need to break the cycle of unnecessary broad-spectrum antibiotic use, which fuels collateral damage and further resistance. In Germany, resistance rates for fluoroquinolones are around 25% and for cephalosporins around 15%, yet broad-spectrum drugs are often prescribed.
Treating chronic prostatitis and recurrent UTIs presents distinct challenges. For chronic prostatitis, less than 10% of cases are bacterial, with the majority being non-bacterial, and antibiotic penetration into the prostate is limited. Recurrent UTIs, more common in females, are increasingly addressed with non-antibiotic strategies and immune-modulating agents, though evidence for some, like cranberry or d-mannose, is not conclusive. Local estrogen therapy is recommended for postmenopausal women.
Research, including the BARICADE consortium, is delving into host-pathogen interactions to identify biomarkers for predicting pyelonephritis, severe disease courses, or recurrent infections. Diagnostic tools like the Acute Cystitis Symptom Score (ACSS) are being developed to streamline clinical decisions and serve as objective symptom assessment in studies. The future of urogenital infection treatment hinges on molecular diagnostics, host immune profiling, and personalized medicine. Rapid point-of-care testing for bacterial presence and susceptibility is crucial, aiming for results within hours rather than days. Immune profiling will stratify patients by risk, driving personalized treatment. While initial costs may be higher, these advanced diagnostic and personalized approaches are expected to become cost-effective, transforming patient care within the next decade.